Moreover, the observed killing of PD-L1 expressing NSCLC cell lines was not affected by gene variations in these tumor cell lines, including the mutations of KRAS (A549 and H358 cells) or EGFR (H1975 cells), and the loss of P53 activities (H358 and H1299 cells). This evidence concerns the gene KRAS and neoplasm.